Table 1 Previous case reports of pneumatosis intestinalis following gefitinib and erlotinib treatment
Year | Author | Age | Sex | EGFR-TKIs | CT findings | Treatment |
|---|---|---|---|---|---|---|
2012 | Shinagare, et al. 1) | N.D. | N.D. | Erlotinib | N.D. | N.D. |
2012 | Iwasaku, et al. 13) | 82 | F | Gefitinib | Intramural air within the intestinal wall | Conservative therapy |
2012 | Lee, et al. 14) | 66 | F | Gefitinib | Intramural air within the intestinal wall, portal venous air, Infarction of liver | Conservative therapy |
2014 | Hughes, et al. 15) | N.D. Three patients | N.D. | Erlotinib and pertuzumab | N.D. | N.D. |
2015 | Ando, et al. 16) | 71 | M | Gefitinib | Intramural air within the intestinal wall, ascites | Conservative therapy |
2016 | Maeda, et al. 17) | 80 | F | Gefitinib | Intramural air within the intestinal wall, pneumoretroperitoneum, | Conservative therapy |
2017 | Current case | 71 | F | Erlotinib | Intramural air within the intestinal wall, pneumoretroperitoneum, pneumomediastinum | Conservative therapy |